AIMS: We studied the induction of monocytic inducible nitric oxide synthase expression and the tumour necrosis factor-alpha system in patients with congestive heart failure. METHODS AND RESULTS: Forty-three congestive heart failure patients and 15 healthy subjects were studied. Antigenic tumour necrosis factor-alpha and its soluble receptors, measured by ELISA, were increased in chronic heart failure and the increase was related to the clinical severity of the syndrome (tumour necrosis factor-alpha from 8.2+/-5.2 in NYHA class II to 18.2+/-7.2 in class III and 26.9+/-13.2 pg. ml(-1)in class IV, P<0.0001 classes III and IV vs class II; soluble tumour necrosis factor receptor I from 1.0+/-0.2 in class II to 2.3+/-1.1 in class III and 5.5+/-3.2 ng. ml(-1)in class IV, P<0.0001 classes III and IV vs class II; soluble tumour necrosis factor receptor II from 2.7+/-0.7 in class II to 4.9+/-1.9 in class III and 8.4+/-5.0 ng. ml(-1)in class IV, P<0.002 classes III and IV vs class II). Monocytic inducible nitric oxide synthase assessed by Western blot, was expressed only in congestive heart failure patients (13 out of 43). The association among monocytic inducible nitric oxide synthase expression, tumour necrosis factor-alpha system activation, neurohormones and other clinical parameters was studied. The univariate logistic regression showed that inducible nitric oxide synthase expression was strictly associated with NYHA class (P<0.05), antigenic tumour necrosis factor-alpha (P<0.01) and its soluble receptors (P<0.05). The multivariate analysis showed that antigenic tumour necrosis factor-alpha was the only predictor for monocytic inducible nitric oxide synthase expression (P<0.05, RR=2.75, CI 1. 34-5.43). CONCLUSIONS: Inducible nitric oxide synthase is expressed in circulating monocytes of patients with severe congestive heart failure. This phenomenon is linked to the activation of the tumour necrosis factor-alpha system. Copyright 1999 The European Society of Cardiology.
AIMS: We studied the induction of monocytic inducible nitric oxide synthase expression and the tumour necrosis factor-alpha system in patients with congestive heart failure. METHODS AND RESULTS: Forty-three congestive heart failurepatients and 15 healthy subjects were studied. Antigenic tumour necrosis factor-alpha and its soluble receptors, measured by ELISA, were increased in chronic heart failure and the increase was related to the clinical severity of the syndrome (tumour necrosis factor-alpha from 8.2+/-5.2 in NYHA class II to 18.2+/-7.2 in class III and 26.9+/-13.2 pg. ml(-1)in class IV, P<0.0001 classes III and IV vs class II; soluble tumour necrosis factor receptor I from 1.0+/-0.2 in class II to 2.3+/-1.1 in class III and 5.5+/-3.2 ng. ml(-1)in class IV, P<0.0001 classes III and IV vs class II; soluble tumour necrosis factor receptor II from 2.7+/-0.7 in class II to 4.9+/-1.9 in class III and 8.4+/-5.0 ng. ml(-1)in class IV, P<0.002 classes III and IV vs class II). Monocytic inducible nitric oxide synthase assessed by Western blot, was expressed only in congestive heart failurepatients (13 out of 43). The association among monocytic inducible nitric oxide synthase expression, tumour necrosis factor-alpha system activation, neurohormones and other clinical parameters was studied. The univariate logistic regression showed that inducible nitric oxide synthase expression was strictly associated with NYHA class (P<0.05), antigenic tumour necrosis factor-alpha (P<0.01) and its soluble receptors (P<0.05). The multivariate analysis showed that antigenic tumour necrosis factor-alpha was the only predictor for monocytic inducible nitric oxide synthase expression (P<0.05, RR=2.75, CI 1. 34-5.43). CONCLUSIONS: Inducible nitric oxide synthase is expressed in circulating monocytes of patients with severe congestive heart failure. This phenomenon is linked to the activation of the tumour necrosis factor-alpha system. Copyright 1999 The European Society of Cardiology.
Authors: Muthiah Vaduganathan; Stephen J Greene; Javed Butler; Hani N Sabbah; Eduard Shantsila; Gregory Y H Lip; Mihai Gheorghiade Journal: Heart Fail Rev Date: 2013-11 Impact factor: 4.214
Authors: Justin R Kingery; Tariq Hamid; Robert K Lewis; Mohamed Ameen Ismahil; Shyam S Bansal; Gregg Rokosh; Tim M Townes; Suzanne T Ildstad; Steven P Jones; Sumanth D Prabhu Journal: Basic Res Cardiol Date: 2017-02-25 Impact factor: 17.165
Authors: Christopher James; Johnny Millar; Stephen Horton; Christian Brizard; Charlotte Molesworth; Warwick Butt Journal: Intensive Care Med Date: 2016-09-30 Impact factor: 17.440
Authors: Mahin Dianat; Esmat Radmanesh; Mohammad Badavi; Seyed Ali Mard; Gholamraza Goudarzi Journal: Environ Sci Pollut Res Int Date: 2015-11-10 Impact factor: 4.223
Authors: John M Toomasian; Mark M P Jeakle; Mark W Langley; Clinton J Poling; Gergely Lautner; Orsolya Lautner-Csorba; Mark M Meyerhoff; Ben Jamin D Carr; Alvaro Rojas-Pena; Jonathan W Haft; Robert H Bartlett Journal: ASAIO J Date: 2020-07 Impact factor: 3.826
Authors: Letizia Tarantini; Matteo Bonzini; Pietro Apostoli; Valeria Pegoraro; Valentina Bollati; Barbara Marinelli; Laura Cantone; Giovanna Rizzo; Lifang Hou; Joel Schwartz; Pier Alberto Bertazzi; Andrea Baccarelli Journal: Environ Health Perspect Date: 2008-09-26 Impact factor: 9.031